[Midodrine (Gutron) treatment of permanent arterial hypotension in a chronic hemodialysis patient].
Chronic hypotension, although unfrequent in uremic patients on hemodialysis, accentuates the deterioration of patients physical state and thus, their general well-being. These patients often experience acute intradialytic symptoms and respond very poorly to conventional therapies. Well tolerated, midodrine is a suitable and effective choice as it raises blood pressure significantly through its effect on peripheral alpha-adrenergic receptors. The authors report observing the use of midodrine by a dialysis patient during the longest time period published to date, documented by a pharmacokinetic study, and that confirms the excellent results and proves long term tolerance for that drug.
Montagnac
R
R
Service de néphrologie-hémodialyse, Centre hospitalier de Troyes.
Clavel
P
P
Delhotal-Landes
B
B
Flouvat
B
B
Poulain
S
S
Schillinger
F
F
D000316:Adrenergic alpha-Agonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002908:Chronic Disease; D006333:Heart Failure / Q000150:complications; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008879:Midodrine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006435:Renal Dialysis
D000316:Adrenergic alpha-Agonists; D008879:Midodrine